Table 1.

Lentiviral shRNA constructs used in the current study

shRNA construct	Target nucleotide sequence (5′−3′)	Reference	KD efficiency (%)
L-309 sh-PTPσ	GCCACACACCTTCTATAAT	Yim et al., 2013	89.7 ± 3.2
L-309 sh-PTPδ	GTGCCGGCTAGAAACTTG	Yim et al., 2013	93.5 ± 1.6
L-315 sh-β-catenin	GCAATCAGCTGGCCTGGTTTG	Han et al., 2018	83.8 ± 8.0
L-315-sh-Abl1/2	AACCTGTACACATTCTGTGTG	Current study	81.4 ± 0.7
L-315-sh-p250RhoGAP	ACAAGAAGCACCAAGTA	Takamori et al., 2000	38.3 ± 5.9
L-315-sh-Ena	TTGTGGAAGAGGTGCGGAA	Current study	71.8 ± 4.0
L-315-sh-MIM-B	CCGGTTCTGCACCTTCATT	Current study	85.6 ± 6.4
L-315-sh-CASK	GCTGAAGCATCCACACATTGT	Current study	78.2 ± 4.1
L-315-sh-Caskin-1	GGAGATCAAGCAACGGCTTCG	Current study	90.6 ± 3.1
L-315-sh-Caskin-2	GCTGATCTCAGGCCAGATTTC	Current study	51.3 ± 7.1
L-315-sh-RIM1	AGTCCACAGGGTAAAGTTC	Spangler et al., 2013	47.4 ± 7.8
L-315-sh-RIM-BP1	GCCAGATCCTCAAGGTGTTTG	Current study	64.2 ± 9.8
L-315-sh-RIM-BP2	GGAGCAAATGTCACAGGATAT	Current study	49.7 ± 9.7
L-315 sh-Liprin-α2	AGCCAGTCTGATTACAGAA	Spangler et al., 2013	74.9 ± 7.6
L-315 sh-Liprin-α3	GCTAACATGAAGAAGCTTCAA	Han et al., 2018	82.1 ± 5.8
L-315-sh-Piccolo	AAGTGCTGTCTCCTCTGTTGT	Spangler et al., 2013	78.8 ± 11.9
L-315-sh-ELKS1	GCTCGGGATGAGTCCATTAAG	Current study	66.3 ± 2.4
L-315-sh-ELKS2	GCAAGGAGCTTGACATTAAGG	Current study	87.6 ± 2.9
L-315-sh-Trio	GCAGTTCCAGCACGCTATTG	Current study	70.1 ± 3.7
L-315-sh-SYD1A	GCAGCTTCTGGTAGAACGTGA	Current study	50.9 ± 8.6
L-315-sh-N-cadherin	GGACAACTGTCAGTCACAAAG	Han et al., 2018	70.3 ± 5.9
L-315-Nrxn TKD	GTGCCTTCCTCTATGACAACT (for Nrxn1); GAACAAAGACAAAGAGTAT (for Nrxn2); and ATGCTACACTTCAGGTGGACA (for Nrxn3)	Um et al., 2014	86.7 ± 3.6